Toggle Summary Dec 22, 2016
Agile Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
Presentation Scheduled on Thursday, January 12th, 2017 at 11:30 AM Pacific Time ...
Toggle Summary Dec 22, 2016
Agile Therapeutics to Present at Biotech Showcase 2017
Presentation Scheduled on Monday, January 9, 2017 at 9:00 AM Pacific Time...
Toggle Summary Jan 3, 2017
Agile Therapeutics Announces Positive Top-line Phase 3 Results
Resubmission of Twirla ® New Drug Application Expected to Address FDA's Complete Response Letter Company Plans to Resubmit NDA in First Half of 2017 Company to Host Conference Call on January 3, 2017 at 5:00 p.m. Eastern Time PRINCETON, N.J., Jan....
Toggle Summary Jan 19, 2017
Agile Therapeutics to Present at Noble Capital Markets' Thirteenth Annual Investor/Equity Conference
Presentation Scheduled on Tuesday, January 31, 2017 at 11:00 am ET...
Toggle Summary Feb 2, 2017
Agile Therapeutics to Present at the 2017 BIO CEO & Investor Conference
Presentation Scheduled on Monday, February 13th, 2017 at 11:00 am ET...
Toggle Summary Feb 14, 2017
Agile Therapeutics to Present at the RBC Capital Markets 2017 Global Healthcare Conference
Presentation Scheduled on February 23, 2017 at 10:00 AM ET...
Toggle Summary Mar 1, 2017
Agile Therapeutics to Present at 29th Annual ROTH Conference
Presentation Scheduled on Monday, March 13, 2017 at 4:30 PM Pacific Time...
Toggle Summary Mar 8, 2017
Agile Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
Current Business Plan Expected to Extend Cash Position and Fund Operations into Q2 2018...
Toggle Summary Mar 16, 2017
Agile Therapeutics Announces a Poster Presentation of its SECURE Phase 3 Study at the Contraceptive Technology 2017 Conference
PRINCETON, N.J., March 16, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company, announced a poster presentation of data from the SECURE Phase 3 clinical trial for its lead product candidate, Twirla ® , (ethinyl estradiol and levonorgestrel transdermal...
Toggle Summary Apr 11, 2017
Agile Therapeutics Announces Results of its Pre-Submission Meeting with FDA
Confirms Plans to Re-submit New Drug Application for Twirla® by the end of the Second Quarter of 2017...